(Q34053786)

30 July 2017

1 reference

title

Effects of obesity on pharmacokinetics implications for drug therapy (English)

1 reference

30 July 2017

0 references

1 reference

Cheymol G

1

1 reference

30 July 2017

publication date

1 September 2000

1 reference

Clinical Pharmacokinetics

30 July 2017

published in

1 reference

30 July 2017

volume

39

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

215-231

1 reference

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

30 July 2017

cites work

1 reference

12 December 2020

The impact of obesity and disease on busulfan oral clearance in adults

1 reference

12 December 2020

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

1 reference

12 December 2020

Therapeutic drug monitoring of vancomycin in a morbidly obese patient

1 reference

12 December 2020

Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers

1 reference

12 December 2020

Effect of acute and chronic exercise on hepatic drug metabolism

1 reference

12 December 2020

Pharmacokinetic considerations in obesity

1 reference

12 December 2020

Lithium pharmacokinetics in the obese

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics

1 reference

12 December 2020

Time trends in obesity: an epidemiological perspective

1 reference

12 December 2020

[Increase in the prevalence of obesity among children aged 4-5 years in a French district between 1988 and 1993]

1 reference

12 December 2020

Anthracycline antibiotic pharmacology and metabolism

1 reference

12 December 2020

Pharmacokinetics of sufentanil in obese patients

1 reference

12 December 2020

Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr

1 reference

12 December 2020

Phenytoin disposition in obesity. Determination of loading dose

1 reference

12 December 2020

Pharmacokinetics of theophylline in obesity

1 reference

12 December 2020

Fluconazole serum concentrations and pharmacokinetics in an obese patient

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application

1 reference

12 December 2020

Lean body mass in obesity

1 reference

12 December 2020

Intravenous ciprofloxacin dosing in a morbidly obese patient

1 reference

12 December 2020

Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

1 reference

12 December 2020

Lean body mass as a predictor of drug dosage. Implications for drug therapy

1 reference

12 December 2020

Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study

1 reference

12 December 2020

Trends in overweight among US adults from 1987 to 1993: a multistate telephone survey

1 reference

12 December 2020

The pharmacokinetics of dexfenfluramine in obese and non-obese subjects

1 reference

12 December 2020

Carbamazepine pharmacokinetics in obese and lean subjects.

1 reference

12 December 2020

Obesity and cardiac function

1 reference

12 December 2020

Clinical pharmacokinetics of drugs in obesity. An update

1 reference

12 December 2020

Clinical pharmacokinetics of fluoxetine

1 reference

12 December 2020

Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection.

1 reference

12 December 2020

Nonalcoholic steatohepatitis

1 reference

12 December 2020

The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Vancomycin pharmacokinetics in normal and morbidly obese subjects

1 reference

12 December 2020

Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass

1 reference

12 December 2020

Significant weight reduction in obese subjects enhances carbamazepine elimination

1 reference

12 December 2020

Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study

1 reference

12 December 2020

Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men

1 reference

12 December 2020

Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers

1 reference

12 December 2020

Factors that may effect the reduction of hunger and body weight following d-fenfluramine administration.

1 reference

12 December 2020

Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Doxorubicin clearance in the obese

1 reference

12 December 2020

Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients.

1 reference

12 December 2020

Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities

1 reference

12 December 2020

Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity

1 reference

12 December 2020

Phenytoin and plasmapheresis: importance of sampling times and impact of obesity

1 reference

12 December 2020

Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects

1 reference

12 December 2020

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

12 December 2020

Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique

1 reference

12 December 2020

Pharmacokinetics and Pharmacodynamics of Triazolam After Two Intermittent Doses in Obese and Normal-Weight Men

1 reference

12 December 2020

Trends in the prevalence of obesity in the French adult population between 1980 and 1991

1 reference

12 December 2020

Intravenous ciprofloxacin disposition in obesity

1 reference

12 December 2020

Comparison of propranolol and sotalol pharmacokinetics in obese subjects

1 reference

12 December 2020

Vancomycin dosing in morbidly obese patients

1 reference

12 December 2020

Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients.

1 reference

12 December 2020

How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.

1 reference

12 December 2020

Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism

1 reference

12 December 2020

Clinical pharmacokinetics of sevoflurane

1 reference

12 December 2020

Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.

1 reference

12 December 2020

Caffeine pharmacokinetics in obesity and following significant weight reduction

1 reference

12 December 2020

10.2165/00003088-200039030-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1030572913

0 references

1 reference